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Background: Breast angiosarcoma is a malignant mesenchymal neoplasm, which accounts for approxi-
mately 2% of all soft tissue sarcomas. Secondary breast angiosarcoma (SBA) may be related to chronic
lymphedema after a mastectomy with lymph node dissection (Stewart Treves syndrome) and previous
radiotherapy for complications from breast radiation treatment. It is a very rare condition; therefore,
diagnosis and management are still a challenge.
Methods: The ANISC collected SBA data by means of a survey sent to all Italian breast centres in the
ANISC. The clinicopathological characteristics and the management of this disease were analysed.
Results: Twenty-four centres participated in this survey in which 112 cases of SBA were analysed. The
median age of the women with SBA was 68.9 years and it appeared approximately 90 months after the
first irradiation for breast cancer. In 92% of cases, a mastectomy was performed without axillary
dissection for those patients having a high grade of SBA (74.2%). The prognosis was worse in the high-
grade cases (overall survival-OS: 36 months) as compared with the low-grade cases (OS: 48 months).
After a follow-up of 5 years, 50.5% of the patients were still alive.
Disease-free survival (DFS) was 35 months, and there were no differences between the groups of patients
with either high- or low-grade histology.nit, viale Albertoni 15, 40126,
egrini).
M. Taffurelli et al. / The Breast 45 (2019) 56e60 57Conclusions: Secondary breast angiosarcoma is a very aggressive disease associated with a short survival
outcome. The surgical approach still remains an important step in the course of treatment; furthermore,
an accurate histological examination is helpful in establishing the prognosis of the patient. A mastectomy
is mandatory. A longer OS was observed in patients with low-grade angiosarcoma as compared to high-
grade angiosarcoma (C.I. 40e57 vs. 31e41 months).
© 2019 Elsevier Ltd. All rights reserved.Introduction
Breast angiosarcoma is a rare and malignant mesenchymal
neoplasm accounting for approximately 2% of all soft tissue sar-
comas having an incidence of 6.8 per 100,000 people per year [1].
Although rare, the incidence of SBA appears to have increased by
approximately 0,9 per 1000 cases over a 15-year period [2], perhaps
reflecting the long latency period for the development of these
tumours following the widespread adoption of adjuvant radio-
therapy for breast cancer. The malignancy of this type of tumour is
due to the endothelial cells lining the blood vessels [3]. There are
two categories of breast angiosarcoma: primary breast angio-
sarcoma (de novo development) and secondary breast angio-
sarcoma (SBA). The latter type of angiosarcoma is cutaneous in
origin, arising from the dermis and subcutis of the irradiated field,
and may or may not actually involve the underlying breast tissue.
Secondary angiosarcoma is associated with two aetiologic factors:
chronic lymphedema after mastectomy with lymph node dissec-
tion (Stewart Treves syndrome) and previous radiotherapy for
breast conserving surgery [4,5].
Secondary breast angiosarcoma is usually found in older women
(60/70 years of age) after a median latency period between radia-
tion for breast cancer and a subsequent diagnosis 6/7 years later [6].
The tumour will often form in the cutaneous tissue and might
secondarily invade the breast parenchyma, accompanied by a
bluish/reddish discoloration of the skin. Its aggressiveness is a pe-
culiarity of this disease, with a propensity for local recurrence and
distant metastasis. A mastectomy is the primary surgical option,
even if the prognosis is poor: 5-year survival rates vary from 28 to
54% [7,8].
Due to the rarity of this pathology, there are few studies con-
cerning SBA in the literature, and the best management alternatives
have not yet been clarified. The aim of the present study was to
analyse the clinicopathological characteristics, and the manage-
ment and follow-up of a patient population with SBA by means of
the experience of the ANISC centres.Methods
The Italian Association of Breast Surgeons (ANISC) is dedicated
to the study of breast pathology. Data from patients with SBA
treated in all Italian breast centres affiliated with the ANISC were
retrieved from 24 institutional databases. Data for this study of SBA
were obtained by means of a survey requesting data. Data
regarding patient characteristics, time of radiation therapy for
breast cancer and interval of the development of angiosarcoma,
type of surgical treatment, tumour grade and follow-up (Fig. 1)
were retrieved and analysed. Metastatic disease at presentation,
sarcomatoid carcinoma, dermatofibrosarcoma of the breast, and
benign, borderline and malignant phyllodes tumours were
excluded from the analysis owing to their different behaviours in
terms of clinical management and prognosis. All diagnoses were
reached using core needle biopsy or excision biopsy, and were
confirmed with a final histological examination. The histologicaltype of tumour was defined according to the World Health Orga-
nization's (WHO) classification system [10,11]; tumour grade was
defined as low- or high-grade. In the follow-up, disease-free sur-
vival (DFS) was defined as the period from the date of the patho-
logical diagnosis of angiosarcoma to any local or regional distant
relapse or death from breast cancer or to the last visit date in the
cases in which no events were reported. Overall survival (OS) time
was measured in months from the date of initial diagnosis to death
or the last available follow-up with a maximum follow-up of five
years. The follow-up also evaluated tumour grade. Statistical anal-
ysis was carried out using SPSS v.18.0 (IBM Corp., Armonk, NY, USA).Results
The survey was presented to all breast centres in the ANISC.
Twenty-four centres received the survey and 18 provided data. Data
from 112 cases of SBA occurring from 1997 to 2016 were collected.
All the cases selected underwent initial conservative surgery for
breast cancer following adjuvant radiotherapy. The diagnosis was
reached after a baseline biopsy of a reddish area associated with a
lump in the breast which had undergone previous surgery for
breast cancer; axillary lymphadenopathy was the first presentation
of disease in only two patients. All the patients were female, with a
mean age of 68.9 years (range 34e93 years) at diagnosis (media
68,9; dev. Standart 11,974). The SBAs developed approximately 90
months after the first radiation for breast cancer and, in the ma-
jority of cases, the total radiation dose delivered to the breast was
50 Gy (range 40e60Gy).
In 92% of the cases (104 patients), a mastectomy was the first
surgical option; only 7% (8 patients) underwent conservative sur-
gery. Eight patients who underwent amastectomy also underewent
axillary dissection/sampling. In four cases, the final lymph node
examination was negative for the presence of metastasis; however,
in two cases more than one metastatic lymph node was found and,
in one case, the data was lost.
Two cases involving a mastectomy also had a contralateral
axillary dissection since it was the first manifestation of the
angiosarcoma.
Histological examinations of the tumour showed aggressive
tumours, with 74.3% being high grade (78 cases) and 25.7% (27
cases) being moderate or low grade; final histology was missing in
7 patients (Table 1).
After surgery for SBA, 46 patients underwent adjuvant therapy
and 44 received no additional treatment after surgery; for 22 pa-
tients, the data were missing (Table 2). In particular, 36 patients
received adjuvant chemotherapy with anthracyclines and taxane-
containing regimens. Radiotherapy was performed in 9 patients
(two patients received both adjuvant treatments) (Table 3). In the
adjuvant chemotherapy group (34 patients), 79% (27 patients) had
a high-grade tumour and their mean survival was 36 months;
instead, 20% (7 patients) had a low-grade tumour and their mean
survival was 39 months (Table 4). In the group which did not un-
dergo adjuvant therapy (44 patients), 68% (30 patients) had a high-
grade tumour and their mean survival was 38 months (p¼ 0,65);
Fig. 1. Questions in the survey.
Table 1
Histology grade of SBA.
HISTOLOGY
Frequency Percent
High grade 78 65%
Low grade 27 28%
Tot. 105 94%
Missing 7 6,3%
Tot. 112 100%
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undergoing adjuvant therapy, the mean survival was 50months(Table 5).
After a 5-year follow-up, approximately 50.5% (49 patients) of
Table 2
Adjuvant therapy after surgery for SBA.
Adjuvant therapy
Frequency Percent
No Adjuvant 44 39,3%
Adjuvant 46 41,1%
Tot. 90 80,4%
Missing 22 19,6%
Tot. 112 100%
Table 3
Type of Adjuvant therapy.
Type of Adjuvant therapy
Frequency Percent
CHT 34 30,4%
RT 7 6,3%
BOTH 2 1,8%
Missing 69 61,6%
Tot. 112 100%
Table 4
Adjuvant therapy in patients divided by histologic grade with the time of Survival.
Adjuvant therapy and Grade tumour
Frequency Percent Survival
Low grade 7 20,6% 39 months
High Grade 27 79,4% 36 months
Tot. 34 100%
Table 5
Patients who NOT underwent to adjuvant chemotherapy divided by histologic grade: the evaluation of survival time.
NO Adjuvant therapy and Grade tumour
Frequency Percent Survival
Low grade 13 30% 50 months
High Grade 30 68% 38 months
Tot. 44 100%
Table 6
Follow up patients.
Follow up
Frequency Percent
ALIVE 49 50,5%
DFS 31 72%
Recurrence 12 27,9%
Missing 6 12,2%
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free, 12 patients had a recurrence and, for 6 patients, the data were
missing (Table 6). In the 12 patients with a recurrence, 8 patients
(66%) had local recurrence and only 4 patients had a distant
metastasis, the majority of which were in the lung.
Comparing clinical outcome in relation to histological grade, it
was observed that the prognosis was worse in patients with a high-
grade angiosarcoma, although therewere no statistically significant
differences between OS of the high-grade tumours as compared to
the low-grade tumours (high-grade OS C.I. 31e41 months vs. low-
grade OS C.I. 40e57 months, Log-Rank p¼ 0.74). A higher mortality
risk was noted in the high-grade group in the first months after
diagnosis (Breslow-Wilcoxon p¼ 0e042). The global OS was 39
months (C.I. 35e44) and the global DFSwas 38months (C.I. 31e45);there were no differences in recurrence rate regarding the histo-
logical or the type of adjuvant therapy (when performed).
Discussion
Secondary breast angiosarcoma is a rare and malignant disease
which mostly affects women who had undergone previous chest
radiotherapy for breast cancer. The cumulative incidence of SBA in
1 per 1000 patients with breast cancer as reparted in literature in
smaller series of 0,9 to 1,1 per 1000 patients [4]. The malignancy of
this disease relates to the aggressiveness of the tumour of the
vascular endothelium, characterised by rapidly proliferating and
extensively infiltrating growth. This specific feature of the disease
correlates with a short survival outcome [13].
M. Taffurelli et al. / The Breast 45 (2019) 56e6060The widespread adoption of conservative breast surgery and
adjuvant radiotherapy in the management of primary breast cancer
has been accompanied by a steady increase in the incidence of SBA.
Secondary breast angiosarcoma is typically a late complication of
adjuvant radiotherapy and, in the present study, it developed
approximately 90 months after the first radiation for breast cancer.
These findings are consistent with those reported in the literature
and, due to the substantial variability in the latency of this disease, a
high index of suspicion is warranted for any patient undergoing
adjuvant radiotherapy, but importantly, angiosarcoma did not
occur in any of the patients who did not receive radiotherapy.
An early diagnosis and the surgical approach are crucial for the
outcome of the disease.
A surgical biopsy must be able to reach a diagnosis of certainty
and then choose the appropriate surgical approach. Unfortunately,
due to the low incidence of the disease, the diagnosis is not reached
early enough. In fact, the clinical signs which occur are not always
easily recognisable; therefore, a histological diagnosis by surgical
biopsy is reached only when other causes have been excluded,
sometimes in an already advanced stage of the disease.
However, nowadays with the advent of specialisation which is
dedicated exclusively to breast disease, this disease is more
frequently recognised, and the diagnosis is promptly reached on
the basis of both clinical signs and the patient's clinical history.
The best surgical approach is definitely a mastectomy without
axillary dissection in order to achieve radical local control of the
disease. In these cases, breast reconstruction should be considered
[8,9].
Although conservative surgery is still used in cases of SBA, no
sufficient data exist to recommend this treatment due to the high
risk of recurrence.
A definitive histological examination is also important in
defining the prognosis of this disease. In fact, a higher grade of
tumour is related to a higher risk of death in the first three years
after diagnosis; this risk is no longer higher in the late course of the
disease since, after the third year, it become equivalent for both
histological grades.
Aggressiveness is a peculiarity of this disease with a propensity
for local recurrence and distant metastasis. There was no proven
benefit of either overall or disease-free survival in patients who
underwent adjuvant therapy as compared to patients who under-
went only surgical treatment but there were not sufficient data to
recommend one strategy over the other. As reported in a recent
published study whose data derive from databases from the
nationwide Netherlands Cancer Registry, the SBA must be treated
with surgery and in particular with mastectomy: radiotherapy after
surgery does not seem to bring a real benefit on survival [12].
A limitation of the present study includes the long period of data
collection and the difficulty regarding the collection of the follow-
up data of the patients. There is no strict recommendation as to
whether chemotherapy should be performed or not in SBAs;
therefore, the choice to administer chemotherapy to patients was
made by the oncologists of the different breast centres.
Conclusions
An SBA is not very frequent and it is often not easy to diagnose
and treat; this le the Authors to carry out a survey aimed at allItalian Breast Units in order to understand the progression of this
disease on a national scale. The collection of these data has served
to analyse the presentation characteristics of SBA and, above all, the
most correct method of diagnosing and treating it.
The result of the present study showed that mastectomy prob-
ably represented the best surgical approach. Vice versa, axillary
dissection should not be mandatory since sarcoma does not usually
spread to the axillary lymph nodes. Furthermore, the final histo-
logical report has become more accurate in predicting the prog-
nosis. According to the existing literature, a high degree of
malignancy appears to be related to a worse prognosis and to the
overall survival rate in these patient categories. However, no clear
benefit was seen as regards the use of adjuvant therapy for this
disease. All these data were gathered by means of a careful follow-
up. In patients with SBA, it is advisable to carry out a clinical follow-
up at least every six months for the first 3 years from the devel-
opment of the disease and, thereafter, every year.
The data collected did not deviate from the existing literature;
therefore, it can be concluded that this disease, although not
frequent, should be diagnosed promptly and treated using a
multidisciplinary approach.References
[1] Li GZ, Fairweather M, Wang J, Orgill DP, Bertagnolli MM, Raut CP. Cutaneous
radiation-associated breast angiosarcoma: radicality of surgery impacts sur-
vival. Ann Surg 2017 Apr;265(4):814e20.
[2] a Lucas DR1Angiosarcoma. radiation-associated angiosarcoma, and atypical
vascular lesion. Arch Pathol Lab Med 2009 Nov;133(11):1804e9. https://
doi.org/10.1043/1543-2165-133.11.1804.
b Author information May DS, Stroup NE. The incidence of sarcoma of the
breast among women in the United States, 1973-1986. Plast Reconstr Surg
1991;87(1):193e4.
[3] Stewart TW, Treves N. Lymfeangiosarcoma in postmastectomy lymphedema.
Cancer 1949;1:64.
[4] Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy
in women with breast carcinoma. Cancer 2001;92:171e80.
[5] Tomasini C, Grassi M, Pippione M. Cutaneous angiosarcoma arising in an
irradiated breast. Case report and review of the literature Dermatology
2004;209(3):208e14.
[6] Fraga-Guedes C, Andre S, Mastropasqua MG, Botteri E, Toesca A, Rocha RM,
Peradze N, Rotmensz N, Viale G, Veronesi P, Gobbi H. Angiosarcoma and
atypical vascular lesions of the breast: diagnostic and prognostic role of MYC
gene amplification and protein expression. Breast Canc Res Treat 2015
May;151(1):131e40. https://doi.org/10.1007/s10549-015-3379-2. Epub 2015
Apr 19.
[7] McGowan TS, Cummings BJ, O'Sullivan B, et al. An analysis of 78 breast sar-
coma patients without distant metastases at presentation. Int J Radiat Oncol
Biol Phys 2000;46:383e90.
[8] Toesca A, Spitaleri G, De Pas T, Botteri E, Gentilini O, Bottiglieri L, Rotmentsz N,
Sangalli C, Marrazzo E, Cassano E, Veronesi P, Rietjens M, Luini A. Sarcoma of
the breast: outcome and reconstructive options. Clin Breast Canc 2012
Dec;12(6):438e44. https://doi.org/10.1016/j.clbc.2012.09.008.
[9] Torres KE, Ravi V, Kin K, et al. Long-term outcomes in patients with radiation-
associated angiosarcomas of the breast following surgery and radiotherapy for
breast cancer. Ann Surg Oncol 2013;20:1267e74.
[10] Fletcher CDM, Unni KK, Martens F. World Health Organization Classification of
tumor:pathology and genetics of tumors of soft tissue and bone. Lyon: IARC
Press; 2002.
[11] Donnel RM, Rosen PP, Lieberman PH. Angiosarcoma and other vascular tu-
mors of the breast. Am J Surg Pathol 1981;5:629e42.
[12] Rombouts AJM, Huising J, Hugen N, Siesling S, Poortmans PM, Nagtegaal ID. de
Wilt JHW.assessment of radiotherapy-associated angiosarcoma after breast
cancer treatment in a Dutch population-based study. JAMA Oncol 2019 Jan 24.
https://doi.org/10.1001/jamaoncol.2018.6643.
[13] Yin Ming, Wang Wenge, J.Drabick Joseph, Harold Harvey A. Prognosis and
treatment of no-metastatic primary and secondary breast angiosarcoma: a
comparative study. BMC Canc 2017;17:295.
